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Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease that ultimately
leads to joint destruction and functional disability. Although the exact etiology of RA is not fully
understood, it is well established that gut microbiota (GM) plays a vital role in the
pathogenesis of RA, with accumulating evidence suggesting that gut dysbiosis induces
a chronic inflammatory response that may be linked to disease development. Of interest,
patients with RA have significant changes in the intestinal microbiota compared to healthy
controls, and several studies have suggested the use of probiotics as a possible adjuvant
therapy for RA. Benefits of probiotic supplementation were reported in animal models of
arthritis and human studies, but the current evidence regarding the effect of probiotic
supplementation in the management of RA remains insufficient to make definite
recommendations. Several different strains of Lactobacillus and Bifidobacteria, as single
species or in mixed culture, have been investigated, and some have demonstrated beneficial
effects on disease activity in RA human subjects. As of now, L.casei probiotic bacteria seems
to be the strongest candidate for application as adjuvant therapy for RA patients. In this
review, we highlight the role of GM in the development and progression of RA and
summarize the current knowledge on the use of probiotics as a potential adjuvant
therapy for RA. We also review the proposed mechanisms whereby probiotics regulate
inflammation. Finally, the role of fermented foods is discussed as a possible alternative to
probiotic supplements since they have also been reported to have health benefits.
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INTRODUCTION
Rheumatoid Arthritis (RA) is a chronic immune-mediated inflammatory disorder that involves the
synovial membranes of multiple joints (Sewell and Trentham, 1993; McInnes and Schett, 2017). The
inflammatory process underlying this disease causes cartilage and bone destruction, damaging the
joint structure and (Kang et al., 2017) leading to functional disability (Firestein, 2003; Smolen et al.,
2016; Kalinkovich et al., 2018). In addition, systemic inflammation may impact other organs and
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systems, such as the cardiovascular, pulmonary, skeletal bone,
and brain (McInnes and Schett, 2011). RA is characterized by
autoantibodies production in most patients, such as rheumatoid
factor and anti-citrullinated protein antibodies (McInnes and
Schett, 2011). Although the exact etiology of RA remains
unknown, it has become evident that besides genetic factors,
the environment (including the internal environment, the
microbiome) plays a pivotal role in disease onset (Scherer
et al., 2020).
RA patients have compositional and functional alterations in the
gut microbiota (GM) (Zhang et al., 2015), and a significant decrease
in microbial diversity compared with healthy controls has been
reported (Chen et al., 2016). Moreover, the GM of RA patients
exhibited decreased diversity with increased disease duration (Chen
et al., 2016). Faecalibacterium is one of the most abundant Firmicutes
in the human gut that produces butyrate, and a decreased abundance
of Faecalibacterium and other butyrate producing taxa, such as
Flavobacterium, have been reported in RA patients (Picchianti-
Diamanti et al., 2018). On the other hand, the GM of RA patients
has a significant increase in the order of Lactobacillales (Chen et al.,
2016; Picchianti-Diamanti et al., 2018), and a higher variety of
lactobacilli compared to healthy controls (Liu et al., 2013).
Accordingly, an increase in the Lactobacillaceae family and the
Lactobacillus genus in mice susceptible to collagen-induced
arthritis (CIA) have been reported (Liu et al., 2016). Interestingly,
the administration of some Lactobacillus species, seems to exert
beneficial effects in RA clinical signs, which suggests that different
Lactobacillimay have different roles in RA pathogenesis and disease
activity modulation (Alipour et al., 2014; Vaghef-Mehrabany et al.,
2014). In early RA patients, a significant increase of Prevotella genus
has been frequently found in comparison to healthy controls, in
particular Prevotella copri (P. copri) (Maeda et al., 2016; Paul et al.,
2021; Reyes-Castillo et al., 2021). Given that the GM of RA patients
differs from the general population and that anti-rheumatic drugs can
exert positive effects on its regulation (Croia et al., 2019), microbiome
research in the field of Rheumatology is expanding significantly
(Manasson et al., 2020). Mounting evidence supports the existence
of a reciprocal connection between drugs and GM, which can
influence each other and have an impact on therapeutic outcomes
(Bhat et al., 2017). Specifically, methotrexate (MTX) was shown to
modify GM composition, partly restoring the microbial balance
altered by the disease (Zhang et al., 2015; Picchianti-Diamanti
et al., 2018). Moreover, the partial restoration of a beneficial
microbiota induced mainly by anti tumor necrosis factor (TNF)
drugs (as shown for etercept) can contribute to the clinical efficacy of
these agents. A deeper understanding of the alterations occurring in
the GM of patients on different therapeutic regimens could help set
up individualized and supportive therapeutic strategies providing
patients with more effective and safe care (Picchianti-Diamanti et al.,
2018). In line with this, GMmodulation and its interactions with the
host have been reported as a strategy to prevent and control
rheumatic diseases (Van De Wiele et al., 2016).
Probiotics are defined as live microorganisms that, when
administered in adequate amounts, confer a health benefit on
the host (Hill et al., 2014). Several studies have suggested the
use of probiotics as a possible adjuvant therapy for RA patients
(Ciccia et al., 2016; Wang et al., 2016; Reyes-Castillo et al., 2021).
Various mechanisms whereby probiotics affect RA have been
proposed, but are still poorly scientifically supported. Currently,
most of the available research on this topic was conducted in
animal models of arthritis. Exogenous bacteria can have a transient
and subject-specific effect on the GM and, by its modification, can
improve dysbiosis-related diseases (Zhang et al., 2016), such as RA.
Since the probiotic effect is strain-dependent (Butel, 2014), the
most appropriate strain must be chosen.
RA is a major global public health challenge with increasing age-
standardized prevalence and incidence (Safiri et al., 2019). Despite
the substantial advances with novel pharmacological therapies, the
impact of RA on patient’s functional capacity and quality of life
remains a significant issue. Most patients have a chronic persistent
form of the disease, as full remission is uncommon and sustained
remission is even more unlikely to occur. Moreover, in order to
control this disease, chronic treatment is needed, and multiple drug
adverse effects often accumulate over the years. Indeed, there are still
considerable unmet needs in RA management, and new safe
treatment approaches that complement the existing ones are
required (Smolen et al., 2016).
This paper aims to provide an up-to-date review of both animal
and human studies investigating the effects of probiotics in RA and
the proposed mechanisms whereby probiotics regulate
inflammation. Since fermented foods can be used as a probiotic
carrier and contain health-promoting components (Melini et al.,
2019), we address their potential use in this context as a possible
alternative to probiotic supplements.
GUT MICROBIOTA, IMMUNE SYSTEM AND
RHEUMATOID ARTHRITIS
It is now well established that more than 100 trillion
microorganisms, primarily bacteria, colonize the human oral-
gastrointestinal tract, most residing in the distal intestine
(Kamada et al., 2013). In recent years, there has been a dramatic
increase in the interest regarding the composition and function of
GM, resulting in a large body of evidence supporting GM as a crucial
component in shaping host physiology and maintaining gut and
immune homeostasis (Derrien and van Hylckama Vlieg, 2015).
The clinical picture of RA results from a complex interaction
between various factors, including autoantibodies and signal
transduction pathways of the innate and adaptive immune
system (Croia et al., 2019). In RA patients, joint tissue is
typically infiltrated by immune cells such as T cells, B cells, and
macrophages, producing a variety of pro-inflammatory cytokines
facilitating inflammation and eventually leading to tissue
destruction (Volkov et al., 2020). Throughout life, GM plays a
fundamental role in the induction, education, and function of the
immune system, as well as the individuals’ response to self-antigens
(Belkaid and Hand, 2014; D’Amelio and Sassi, 2018; Wu and Wu,
2012). The modulation of GMmay regulate the mechanism of gut
immune tolerance, as it influences the number and function of
colonic regulatory T cells (Tregs) (Tanoue et al., 2016). Tregs
suppress inappropriate activation of effector T cells by secreting
anti-inflammatory cytokines (Kalinkovich and Livshits, 2019;
Kayama et al., 2020). On the other hand, the mucosal immune
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system has a crucial role in developing and maintaining a healthy
GM (X. Wu et al., 2016). Due to this interdependent relationship,
gut dysbiosis, a compositional and functional alteration of GM
(Levy et al., 2017), may influence host susceptibility to many
immune-mediated diseases such as RA, type 1 diabetes, multiple
sclerosis, and systemic lupus erythematosus (de Oliveira et al.,
2017). Additionally, there is emerging literature reporting on the
role of changes in GM in the pathogenesis of chronic immune-
mediated inflammatory disorders, including RA (Ciccia et al., 2016;
Kalinkovich et al., 2018; Zhong et al., 2018). Deregulation of host
responses as a consequence of gut dysbiosis could affect distant
anatomical sites through the activation of host immune responses,
and this could be the mechanism contributing to the onset of an
idiopathic inflammatory condition like RA (Cho and Blaser, 2012).
To support the hypothesis that changes in GM composition play a
significant role in the onset and progression of RA (Horta-Baas et al.,
2017; Kang et al., 2017), several mechanisms by which GM is
associated with arthritis have been proposed. These include
regulating the host’s immune system (triggering T cell
differentiation), activating antigen-presenting cells (APCs) through
an effect on Toll-like receptors (TLRs) or NOD-like receptors
(NLRs), promoting the citrullination of peptides by enzymatic
action, antigenic mimicry, and increasing the intestinal mucosal
permeability (Horta-Baas et al., 2017; Guerreiro et al., 2018).
Regarding the effect on the expression of TLRs of APCs, this may
contribute to an imbalance in the Th17/Treg cell ratio and this local
immune response could lead to systemic autoimmunity (Horta-Baas
et al., 2017). Thus, the existing literature suggests that GM could
contribute to or prevent the expansion of autoimmunity and
inflammation during the preclinical and clinical phases of RA,
and GM could influence transitions between these phases (Wilson
et al., 2020). Figure 1 summarizes the pathophysiology of RA and the
proposed mechanisms whereby GM could participate in triggering
autoimmunity and systemic inflammation in susceptible individuals.
Since the diet is an essential environmental factor impacting
intestinal microbiota composition, increasing attention has been
given to its role in the pathogenesis, progression, and activity of
rheumatic diseases (Gioia et al., 2020). In this regard, the use of
probiotic bacteria has been suggested as a possible strategy to
correct gut dysbiosis and promote the homeostasis of a healthy
microbiota, having an impact on systemic immune responses and
thus could be used as adjuvant therapy to treat immune-mediated
diseases (Gareau et al., 2010; de Oliveira et al., 2017).
MECHANISMS UNDERLYING PROBIOTICS
EFFECTS ON GUT MICROBIOTA, IMMUNE
SYSTEM AND RHEUMATOID ARTHRITIS
A link between the composition and activity of GM and human
health and disease has been previously described (Azad, Sarker, Li,
et al., 2018). Although the local effects of probiotic bacteria on gut
health are well reported, the mechanisms behind their systemic anti-
inflammatory and immunomodulating potential have not been
wholly explored (Vieira et al., 2016; Plaza-Diaz et al., 2019;
Oliviero and Spinella, 2020). A set of mechanisms whereby
probiotics regulate inflammation have been postulated, which can
be exerted not only via direct immune system modulation, but also
through indirect mechanisms (La Fata et al., 2018; Kalinkovich and
Livshits, 2019).
Probiotic’s Direct Mechanisms of Immune
System Modulation
Specific probiotic bacteriamodulate the immune response by affecting
different cells involved in innate and acquired immunity, such as
epithelial cells and dendritic cells (DCs), natural killer cells (NK),
macrophages, and lymphocytes (Bermudez-Brito et al., 2012; La Fata
et al., 2018; Cristofori et al., 2021).
FIGURE 1 | Rheumatoid arthritis pathophysiology and the proposed mechanisms by which gut microbiota could influence its pathogenesis. CRP, C-reactive; P.
Copri, Prevotella copri; ZO-1, Zonula occluclens-1; IL, Interleukin; TNF, tumour necrosis factor.
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The innate immune system develops the primary response to
pathogens after activation of the pattern recognition receptors
(PRRs), which are expressed on immune and non-immune
cells, such as NK cells, DCs, macrophages, fibroblasts, and
epithelial cells (Bermudez-Brito et al., 2012; Plaza-Diaz et al.,
2019; Cristofori et al., 2021). Toll-like receptors (TLRs) are the
most widely studied PRRs, which can activate signaling pathways
that affect cell proliferation and cytokine production to modulate
the immune system (Ferlazzo et al., 2011; Cristofori et al., 2021). It
is well established that probiotics can downregulate TLR
expression, reducing inflammation (Gómez-Llorente et al., 2010).
Concerning the adaptive immune response, T cells are central to
immune balance (Plaza-Diaz et al., 2019). Inflammatory responses
driven by T helper (Th)1 and Th17 cells protect the host from
pathogens, but their overactivation is linked to the pathogenesis of
detrimental inflammation. The adaptive immune cells Foxp3+
Tregs suppress inappropriate activation of effector Th cells by
secreting anti-inflammatory cytokines, such as IL-10, modulating
the immune response (Kalinkovich and Livshits, 2019; Peters et al.,
2019; Kayama et al., 2020). Probiotics have also been reported to
influence cytokine production by APCs, which initiates adaptive
responses (Azad, Sarker, and Wan, 2018). Beyond the described
immunomodulatory properties involving DCs and T cells, some
probiotic strains also have a role in increasing the production of
secretory IgA once they promote the differentiation of B cells into
plasma cells (Liu, Tran, et al., 2018). Secretory IgA provides a
defense against pathogens by limiting bacterial adhesion to the
epithelium and preventing the penetration of host tissue (Azad,
Sarker, and Wan, 2018; Liu, Tran, et al., 2018).
Probiotic’s Indirect Mechanisms of Immune
System Modulation
Probiotics can also interact with the host immune system through
indirect mechanisms, which involve the modulation of GM. The
mechanisms by which probiotic strains have been proposed to
modulate GM include regulating the gut epithelial barrier and the
mucus layer characteristics, secretion of antimicrobial
compounds and competition with pathogenic bacteria (Vieira
et al., 2016; Jethwa and Abraham, 2017; Cristofori et al., 2021).
The gut epithelium, which separates the luminal environment from
the intestinal milieu, has a key role in assuring the permeability to
nutrients and other molecules, as well as blocking the entry of toxins
and other microorganisms (Deane et al., 2017; Van Spaendonk et al.,
2017). Tight Junction (TJ) proteins, located in the apical part of the
intestinal epithelial cells, are crucial elements to ensure the functionality
and integrity of the mucosal barrier (Ulluwishewa et al., 2011; Lee,
2015). When an alteration in the expression or localization of TJ
proteins occurs, the epithelial barrier function is compromised due to
increased permeability (Ulluwishewa et al., 2011). The use of probiotics
and the consequent increase in the short-chain fatty acids (SCFA)
release, particularly butyrate, has been reported to enforce the gut
barrier function as butyrate strengthens the barrier through increased
expression of TJ components zonula occludens (ZO)-1, ZO-2, and
cingulin (Bordin et al., 2004; Deane et al., 2017; Liu, Tran, et al., 2018).
The intestinal epithelium is covered by a viscoelastic mucus layer,
mainly composed of mucins, high-molecular-weight glycoproteins
produced by goblet cells (La Fata et al., 2018). Mucins are responsible
for building a protective barrier containing digestive enzymes,
promoting food passage, and at the same time prevent the entry
of bacteria into the lamina propria by blocking their adhesion to the
epithelial cells (Corfield et al., 2000; Derrien et al., 2010; De Santis
et al., 2015). The intestinal mucus layer has a primary role in
protecting against mechanical, chemical, and biological attacks to
the gut and contributes to the maintenance of intestinal homeostasis
(Paone and Cani, 2020). Some probiotic strains have been reported to
regulate mucin expression, altering the properties of the mucus layer
and indirectly regulating the gut immune system (La Fata et al., 2018).
Examples include the adherent Lactobacillus spp, which can stimulate
MUC3 expression in human intestinal epithelial cells and MUC2
production and secretion (Sicard et al., 2017; Bron et al., 2017), and
Lactobacillus reuteri (L. reuteri), which has a protective effect against
dextran sulfate sodium-induced colitis in mice, increasing the mucus
layer thickness (Ahl et al., 2016).
Specific probiotic-modulated local and systemic metabolites have
been reported to have anti-inflammatory and antimicrobial
functions, such as SCFA, dietary tryptophan, adenosine, and
histamine (Liu, Alookaran, et al., 2018). One of the primary
mechanisms by which probiotics compete in this environment is
through competitive exclusion, by which they adhere to the intestinal
mucosa and prevent the subsequent entry of pathogens into the
lamina propria (Liu, Tran, et al., 2018; Santis et al., 2015). Moreover,
the adhesion of probiotic microorganisms to epithelial cells may
trigger a signaling cascade, leading to immunological modulation
(Markowiak and Sli_, 2017). As previously described, SCFAs exert an
indirect anti-inflammatory effect through improving intestinal
barrier function (Bodkhe et al., 2019; Kolodziejczyk et al., 2019).
Butyrate is particularly relevant in modulating inflammation, as it
inhibits histone deacetylase and regulates the expression of numerous
pro-inflammatory genes, inducing the differentiation and expansion
of Tregs and regulating cytokine production (Koh et al., 2016; Liu
et al., 2021; Liu, Tran, et al., 2018; Peters et al., 2019).
Probiotic’s Mechanisms and the
Pathophysiology of Rheumatoid Arthritis
Crosstalk between gut epithelium, immune system, and commensal
bacteria is key to starting the systemic inflammatory response (Y. Liu,
Tran, et al., 2018). An imbalance between anti-inflammatory and
pro-inflammatory cytokines, including interleukin (IL)-1β, TNF,
interferon (IFN)-γ, IL-6, IL-12, and IL-17, plays a central role in
the inflammatory processes involved in the pathogenesis of RA
(Smolen and Steiner, 2003; So et al., 2008; Amdekar et al., 2011).
The proposed mechanism for the gut-joint axis in
inflammatory arthritis is related to the hyperpermeability of
the gut wall, which leads to the exposure of immune system to
microorganisms, leading to a systemic immune response that
triggers a local inflammatory process within the joints (Jethwa
and Abraham, 2017; Liu et al., 2021).
Considering the perturbed GM as a pivotal trigger in the
pathogenesis of RA, interest has emerged regarding the clinical
interest of probiotics to correct gut dysbiosis and downregulate
the pro-inflammatory cytokine cascade implicated in
inflammatory arthritis (Wang et al., 2016; Mohammed et al.,
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2017; Lowe et al., 2020). Probiotics upregulate regulatory
cytokines produced by Tregs or tolerogenic DCs in the gut.
Cytokines travel to target organs and expand Tregs that traffic
to inflammation sites (Marietta et al., 2016). Probiotic-driven
metabolic products, such as SCFA, also impact immune response
and systemic inflammation by regulating immune cell function
(Oliviero and Spinella, 2020). SCFA as regulators of several
leukocyte functions including production of eicosanoids and
chemokines and cytokines, such as TNF, IL-2, IL-6 and IL-10,
exhibit anti-inflammatory properties (Vinolo et al., 2011;
Kalinkovich and Livshits, 2019). Moreover, probiotic bacteria
and its metabolic products can keep a balance between tolerance
to the intestinal microflora and resistance against harmful
bacterial colonization, adherence, and translocation
(Mohammed et al., 2017). These properties may be useful to
correct the hyperpermeability of gut wall proposed for the gut-
joint axis in inflammatory arthritis.
A meta-analysis of randomized trials investigating the effect of
Lactobacillus as single species or in mixed cultures with
Bifidobacterium species concluded that probiotic supplementation
reduced serum levels of IL-6 (Mohammed et al., 2017). Another
systematic review and meta-analysis that investigated the
effectiveness of Lactobacillus casei (L. casei) supplementation in
RA reported that a significant reduction of C-reactive protein
(CRP) was achieved with this specific strain (Rudbane et al.,
2018). Studies have also reported that L. casei might help alleviate
RA symptoms and suppress pro-inflammatory cytokines in
individuals undergoing treatment with disease-modifying anti-
rheumatic drugs (DMARDs), which suggests a positive synergistic
effect between DMARDs and probiotics on arthritis (Alipour et al.,
2014; Pan et al., 2017, 2019).
These findings suggest that the administration of probiotic
bacteria may have a beneficial effect on the inflammatory activity
of RA, through the regulation of cytokine production,
improvement of the intestinal barrier function, and its positive
synergistic effect with DMARDs. Figure 2 summarizes the
proposed mechanisms for the influence of probiotics on RA.
EXPERIMENTAL EVIDENCEOF PROBIOTIC
EFFECTS ON RHEUMATOID ARTHRITIS
PREVENTION AND TREATMENT
Experimental Evidence From Animal
Models
This section will review the current evidence for microbiome
manipulation by using probiotic bacteria in animal models of
arthritis for both disease prevention and treatment.
Studies With the Collagen-Induced Arthritis Animal
Model
Several studies have proposed a link between GM and CIA
development with oral administration of several bacterial
strains in mice.
A study conducted by Fan et al. compared the effects of a
preventive and therapeutic treatment with Bifidobacterium
adolescentis (B. adolescentis) in CIA rats (Fan et al., 2020).
Preventive B. adolescentis administration had better results in
FIGURE 2 | Proposed mechanisms for the influence of probiotics on systemic inflammation in rheumatoid arthritis patients. IgA, Immunoglobulin A; IL, Interleukin;
RA, Rheumatoid; SCFA, short Chain Fatty Acids; TJ, Tight Junctions; TLR, Toll-like receptors.
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reducing the clinical symptoms, rebalancing the pro- and anti-
inflammatory responses, and reversing the gut dysbiosis than late
B. adolescentis treatment. Early probiotic administration
performed better in promoting SCFAs production, had
significant higher Tregs cells frequency and lower levels of
TNF compared to the late B. adolescentis treated group.
Moreover, SCFA positively correlated with Tregs and
negatively correlated with pro-inflammatory cytokines in the
early treated group (Fan et al., 2020). These findings suggest
that the introduction of B. adolescentis before arthritis can impact
the onset of arthritic inflammation, and support that GM
manipulating therapies should be provided at an early stage of
the disease or even before disease occurrence.
Another study investigated the effects of the oral administration
of L. casei Shirota (LcS) in amousemodel of CIA (Kato et al., 1998).
LcS administration during induction of CIA suppressed the
abnormal anti-type II collagen antibody production and delayed
onset and reduced severity of CIA. It was concluded that oral
administration of LcS reduced the humoral and cellular immune
responses to CIA, which could result in reduced rates of CIA
development in mice (Kato et al., 1998).
Yamashita et al. evaluated the effect of oral administration of
L. helveticus SBT2171 in reducing the incidence and progression
of CIA (Yamashita et al., 2017). Oral administration of L.
helveticus SBT2171 significantly relieved joint swelling and
suppressed weight loss. These findings suggested that L.
helveticus SBT2171 can downregulate the abundance of
immune cells and the production of anti-type II collagen
antibodies and IL-6, suppressing CIA symptoms indicating its
potential for use in the prevention of RA (Yamashita et al., 2017).
Amdekar et al. assessed the therapeutic efficacy of L. casei in a
CIA model of arthritis and reported a therapeutic effect of this
probiotic when administered after the onset of arthritis (Amdekar
et al., 2011). There was a significant reduction in the arthritis
score with a significantly decreased secretion of pro-
inflammatory cytokines (TNF and IL-6) and an increased
concentration of IL-10, an anti-inflammatory cytokine
(Amdekar et al., 2011). The authors suggested that the exerted
anti-inflammatory effect of L. casei was a result of
Cyclooxygenase (COX)-2 and NF-κB inactivation (Amdekar
et al., 2011). Previous research on the COX-2 have already
sugested that it has a key role in inflammation in RA (Kang
et al., 1996), as COX-2 has been pointed out as the responsible for
the overproduction of prostaglandins. Prostaglandins are
implicated in different phases of inflammatory reactions, and
its synthesis is down regulated by anti-inflammatory cytokines,
such as IL-10. In this regard, the proposed mechanism provided
by Amdekar et al. for the obtained effect with L. casei in a CIA
model, involves prostaglandins inhibition due to an increased
secretion of IL-10 promoted by the probiotic treatment.
Another study from Amdekar et al. evaluated the anti-
inflammatory and antioxidant properties of L. casei and
Lactobacillus acidophilus (L. acidophilus) as a therapeutic
protocol in an experimental model of CIA. The results
suggested that L. casei and L. acidophilus exhibit antiarthritic
and anti-inflammatory properties by suppressing IL-6, TNF, IL-
17, and IL-1β production and upregulating IL-10 and IL-4
(Amdekar et al., 2013). Along with the reported imbalances
between pro-inflammatory and anti-inflammatory cytokines,
which have been reported to play an important role in
initiation and pathogenesis of arthritis, prostaglandins, nitric
oxide, and reactive oxygen species (ROS) are also released at
the site of inflammation in many rheumatic diseases, damaging
the cartilage and the components of extracellular matrix. In this
study, L. casei and L. acidophilus significantly decreased lipid
peroxidation and catalase (CAT) levels, and increased the
concentration of glutathione peroxidase (GPx), glutathione
(GSH) and superoxide dismutase (SOD) (Amdekar et al.,
2013). These findings are particularly relevant as they suggest
that the beneficial effects of L. casei and L. acidophilus are due, not
only to their anti-inflammatory effect, but also to their
antioxidant properties.
In a study conducted by Marietta et al., an isolated human gut
commensal Prevotella histicola (P. histicola) was tested for treating
CIA in HLA-DQ8 transgenic mice in prophylactic and therapeutic
protocols (Marietta et al., 2016). Mice were monitored for the onset
and progression of CIA. Treating mice with P. histicola
significantly decreased the incidence and severity of arthritis
compared to controls (Marietta et al., 2016). The microbial
modulation of arthritis was dependent on the generation of
Tregs in the gut, resulting in suppression of Th17 response and
increased release of IL-10. Moreover, treatment with P. histicola
improved intestinal barrier function by increasing the expression of
TJ proteins, ZO-1 and occludin (Marietta et al., 2016).
So et al. investigated the effect of L. casei in suppressing the
inflammatory immune responses of RA by testing its impact on
the effector functions of CD4+ T cells (So et al., 2008). This study
demonstrated that L. casei could effectively suppress RA-related
pathways by simultaneously down-regulating Th1 effector
functions and upregulating anti-inflammatory IL-10 (So et al.,
2008). Additionally, oral administration of L. casei suppressed
arthritis, reduced hind paw swelling, lymphocyte infiltration and
the destruction of cartilage tissue. Several reports have
demonstrated the beneficial effects of Lactobacillus species in
mouse models of arthritis however further research is needed to
describe the mechanisms underlying its efficacy.
Animal studies support the thesis that L. casei strains down-
regulate immune-system function (Vaghef-Mehrabany et al.,
2018), which is beneficial in the case of RA and other
inflammatory diseases. Results from a number of preclinical
studies have demonstrated that various strains of L. casei can
be effective in reducing arthritis score and decreasing serum
inflammatory cytokines in RA (Kato et al., 1998; So et al., 2008;
Amdekar et al., 2011, 2013; Pan et al., 2019). Although there are
numerous studies reporting the efficacy of Lactic Acid Bacteria
(LAB), their underlying mechanisms of action are still to be fully
elucidated. Proposed mechanisms for L. casei strains include the
improved proportion of Th2/Th1 cytokines, including the
induction of Treg cells and down-regulation of Th1 cells.
Once bound to TLR 2/6, L. casei bacteria, trigger various
intracellular mechanisms, which will ultimately contribute to
the maturation of FoxP3-CD4+ towards FoxP3 Treg cells
(Vaghef-Mehrabany et al., 2018). Tregs cells are the main
producers of IL-10, providing inhibitory effects on Th1 cells
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(Issazadeh-Navikas et al., 2012). Amdekar et al., have also proposed
a similarmechanism for Lactobacillus species (Amdekar et al., 2013).
Therefore, the altered cytokine balance in favour of anti-
inflammatory cytokines seems to be the main mechanism of
action of probiotics in RA and should be the basis of future
research. The role of antioxidant effects should be further elucidated.
Studies With the Adjuvant-Induced Arthritis Animal
Model
Concerning the role of probiotic bacteria on disease progression,
Pan et al. investigated the potential of administrating L. casei in
the treatment of adjuvant-induced arthritis (AIA) and reported
profound changes of microbial species in the gut as well as
alterations in clinical signs during arthritis induction and
progression phases, such as inhibition of joint swelling, lower
arthritis scores, and prevention of bone destruction (Pan et al.,
2019). Thirty days after prophylactic treatment with L. casei, a
significant reduction in pro-inflammatory cytokines levels was
observed. Moreover, an increased relative abundance of several
Lactobacillus strains was also detected, such as L. acidophilus,
Lactobacillus hominis, L. reuteri, and Lactobacillus vaginalis,
suggesting that L. casei improves arthritis mainly through
establishing the rebalance of the Lactobacillus strains (Pan
et al., 2019). Some Lactobacillus strains have been reported to
drive T cell differentiation from intraepithelial CD4+ T cells into
immunoregulatory Treg. Also, their metabolic products, such as
SCFAs, influence colonic Treg cell homeostasis (Smith et al.,
2013; Cervantes-Barragan et al., 2017).
Rovensky et al. investigated the efficacy of Escherichia coli O83
(Colinfant®) in the treatment of AIA (Rovenský et al., 2009). They
studied the effect of Colinfant® alone, of Colinfant® in combination
with MTX and MTX alone. They found a significant reduction in
both inflammation and arthritis-associated alterations (reduction
of hind paw swelling and arthrogram score) with MTX and with
the combination of MTX and Colinfant® (Rovenský et al., 2009).
They also reported a more significant improvement of the arthritis
score with combination treatment than withMTX alone. However,
the use of Colifant® alone had no impact on inflammatory markers
(Rovenský et al., 2009).
Another study using an AIA model investigated whether B.
coagulans and inulin, administered either isolated or in
combination, influenced arthritis severity in rats (Abhari et al.,
2016). A significant clinical improvement was observed in B.
coagulans and/or inulin treated rats. This improvement included
suppression of paw swelling and a decrease in pro-inflammatory
parameters, such as fibrinogen and TNF-α (Abhari et al., 2016).
A study conducted by Achi et al. evaluated three strains of
Bifidobacteria, namely Bifidobacterium breve NCIM 5671 (B.
breve NCIM 5671), Bifidobacterium longum NCIM 5672, and
Bifidobacterium bifidum NCIM 5697, to investigate their
prophylactic effect in an AIA model (Achi et al., 2019). The
results have demonstrated that Bifidobacteria can reduce the
severity and progression of arthritis. However, B. breve NCIM
5671 had better antiarthritic effects in the rat model than the
other bifidobacterial species studied, suggesting that the effect is
strain-dependent, and these strains should be further explored for
their putative positive impact on RA treatment (Achi et al., 2019).
Table 1 summarizes the characteristics and main findings
regarding probiotic effects on RA in preclinical studies.
Summary of Evidence From Animal Models
Even after several decades of research, RA remains a complex disease
of unknown etiology and without a cure (Choudhary et al., 2018).
Animal models are widely used for testing potential new therapies
for RA, and despite their recognized limitations, it is evident that
these have provided valuable information regarding RA
pathogenesis and the underlying mechanisms of disease. When
considering all existing animal models of arthritis, the most
commonly found question is which model is most predictive of
therapeutic efficacy in human subjects with RA, as each model
features a different mechanism driving disease expression (Hegen
et al., 2008). Considering the problem to be investigated, the benefits
of each model should be closely evaluated in order to make the most
appropriate choice. Accordingly, for the identification and validation
of drug targets, AIA and CIA models have great reproducibility and
are the most commonly used models (Choudhary et al., 2018). The
AIA model is characterized by acute inflammation and severe
destruction, useful for the evaluation of the early structural
consequences of arthritis and also for studies of pain pathways
(Boissier and Bessis, 2017; Vidal et al., 2018). On the other hand, CIA
has been an extremely popular model since its conception, once its
underlying mechanisms involve numerous elements of the innate
and adaptive immune systems, making it a useful model both for
developing concepts to be extended to human subjects and for
validating new treatment targets (Boissier and Bessis, 2017). The
breach of tolerance and generation of auto antibodies towards self,
are recognized as the most important characteristics of the CIA
model, which makes it a very good in vivo model for RA studies
(Asquith et al., 2009).
We have considered both prophylactic (when probiotic
administration started before immunization or before arthritis
onset) and therapeutic (when dosing with study probiotic started
after clinical signs of disease) treatment regimens with probiotic
bacteria in CIA and AIA models. A number of preclinical studies
reported the beneficial effects of probiotics via multiple pathways,
including restoring the dysbiosis of GM in a prophylactic way
(Achi et al., 2019; Pan et al., 2019; Fan et al., 2020). A study
conducted by Liu et al., has reported significant differences in the
microbiome composition of CIA-susceptible and CIA-resistant
mice (Liu et al., 2016). When transplanted to germ-free mice, the
microbiome of the CIA-susceptible mice aggravated CIA disease
severity, suggesting a relationship between GM composition and
CIA susceptibility (Liu et al., 2016). These results showed that
intestinal microbiota strongly affects the balance between pro-
and anti-inflammatory immune responses in CIA. Although
several studies reported differences in the microbiome
composition of RA when compared to controls, little is known
about the highly personalized microbiome dynamics during the
induction, progression, and treatment of arthritis. The genus
Lactobacillus is significantly more abundant prior to arthritis
onset in CIA-susceptible mice than in CIA-resistant mice (Liu
et al., 2016), However, results obtained by Pan et al., indicated
that L. casei could influence the disordered microbiome and
ameliorate arthritis via modulation of Lactobacillus strains
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TABLE 1 | Probiotic effects on animal models of arthritis.
Animal models of CIA
Author, year Study objective Animal model/
administration timing
Probiotic strain Administration dose Evaluated parameters Main findings
Kato et al.
(1998)
To investigate the effects of L. casei Shirota
on the development of CIA and immune
responses
Male DBA 1 mice/after
arthritis modeling
L. casei Shirota PG1: 0.25 × 109 CFU/
day
PG2: 0.5 × 109 CFU/day
PG3: 1 × 109 CFU/day
PG4:2 × 109 CFU/day
Arthritis score; incidence of CIA; serum anti-
CII antibodies; IFN-γ; IL-4
L. casei Shirota ↓ arthritis incidence in all
groups; ↓ arthritis severity; ↓ CII-specific
antibodies IgG2a and IgG2b; ↓ IFN-γ
So et al.
(2008)





L. casei 5 × 109 CFU/dose Paw swelling; arthritis score; CII-specific
antibodies; CII-reactive pro-inflammatory
molecules
L.casei ↓ hind paw swell ing; ↓ lymphocyte
infi l trat ion; ↓ destruction of cart i lage
tissue; ↓ IL-1β; ↓ IL-2; ↓ IL-6; ↓ IL-12; ↓ IL-
17; ↓ IFN-γ; ↓ TNF; ↓ COX-2; ↑ IL-10; ↓
serum CII-specific IgG2a and IgG2b; ↓ T
cell proli feration (in both the
pretreatment and acute phase treatment)
Amdekar
et al. (2011)
To investigate the therapeutic efficacy of L.
casei in a CIA model
Female wistar rats/after
arthritis induction
L.casei ATCC 334 2 × 108 CFU/ml Arthritis score; serum cytokines; hind knee
joint morphology
L. casei ↓ arthritis score; ↓ IL-6; ↓ TNF-α; ↓




To evaluate antioxidant and anti-
inflammatory potential of L. casei and L.
acidophilus in a CIA model
Male wistar rats/after
arthritis induction
L.casei ATCC 334 L.acidophilus
ATCC314
PG1: 2 × 108 CFU/ml
(L. casei)
PG2: 2 × 108 CFU/ml
(L. acidophilus)
Arthritis score; serum cytokines; oxidative
stress markers (GSH, CAT, SOD, lipid
peroxidation, GPx)
L. casei and L. acidophilus ↓ arthritis score; ↑ IL-
4; ↑ IL-10; ↓ IL-6; ↓ TNF; ↓ IL-1β; ↓ IL-17; ↓CAT;
↓ lipid peroxidation; ↑ GSH; ↑ GPx; ↑ SOD
Marietta et al.
(2016)




P. histicola 1 × 109 live bacteria Arthritis incidence; arthritis onset; arthritis
severity; expression of TJ proteins; serum
cytokines
P. histicola ↓ incidence of arthritis; ↓ severity of
arthritis; ↓ IL-2; ↓ IL-17; ↓ TNF; ↑ IL-4; ↑ IL-10;




To evaluate the effect of L. helveticus on the
development of CIA, antibody production
and immune cells
Male DBA 1J mice/after
arthritis induction




Hind limb joint tissues; serum CII-specific
antibodies; serum cytokines; total immune
cells
L. helveticus oral administration ↓ joint
swelling; ↓ body weight loss; ↓ serum CII-
specific IgG and IgG1; L. helveticus
intraperitoneal inoculation ↓ arthritis
incidence; ↓ joint damage; ↓ serum IL-6; ↓




To investigate the effects of B. adolescentis
before and after arthritis induction on GM








5 × 109 CFU/ml/day
(per strain)
Ankle thickness; arthritis score; serum
cytokines; serum anti-CII antibodies; tregs in
MLNs; level of TJ proteins; GM composition;
faecal SCFA
Preventive B. adolescentis performed
better in ↓ ankle thickness; ↓ arthritis score;
↓TNF; ↑ Tregs in MLNs; ↑ SCFAs; ↑ mRNA
level of ZO-1 and occludin; maintaining the
gut microbial communities similar to the CG
Animal models of AIA
Rovenský et
al. (2009)
To evaluate the effect of E. coli O83 on AIA
during basal treatment with MTX
Male lewis rats/after
arthritis induction
E. coli O83 8 × 108 bacteria/ml
(1 ml/kg body mass)
Body mass; hind paw swelling; arthrogram
score; serum albumin




To investigate the possible influence of




Bacillus coagulans 109 spores Paw thickness; Fn; SAA; TNF-a; a1AGp Pretreatment with Bacillus coagulans ↓ Fn; ↓
SAA; ↓ TNF


































(Pan et al., 2019). These findings highlighted the importance of
monitoring changes in microbial communities during disease
progression and provided powerful evidence to explain the
evolution of the GM in RA. Of interest, Fan et al. reported the
beneficial effects of early treatment in maintaining gut microbial
communities (Fan et al., 2020).
There is no model fully reproducing a human rheumatic
disease, which means that therapeutic interventions in animal
models only provide partial information (Bessis et al., 2017).
However, the development of novel treatment interventions for
RA still relies on the careful analysis of studies in animal models
combined with clinical observations.
Experimental Evidence From Human
Studies (Randomized Controlled Trials)
Randomized Controlled Trials With Lactobacillus
rhamnosus
The effect of probiotic supplementationwas studied in stable RA in a
randomized controlled trial (RCT) evaluating the treatment with
Lactobacillus rhamnosus (L. rhamnosus) GG versus placebo
(Hatakka et al., 2003). Patients were not under treatment with
DMARDs, but most of them were on stable medication with
glucocorticoids (GC, 75% in the probiotic group and 62% in the
placebo group) and non-steroidal anti-inflammatory drugs
(NSAIDs, 75% in the probiotic group and 77% in the placebo
group). In this study, the intervention group was given two capsules
of L. rhamnosus (ATCC 53103) GG (Gefilus®, Valio Ltd.; ≥5 × 109
colony-forming units (CFU) per capsule), twice a day, for
12 months, and the placebo group received identical capsules
without the bacteria. There were no statistical differences in the
clinical parameters, biochemical variables, and Health Assessment
Questionnaire (HAQ) between groups. Inflammatory parameters
were not significantly reduced. Interestingly, although there were no
statistical differences in disease activity, more subjects in the
intervention group reported subjective well-being when compared
to the placebo group (Hatakka et al., 2003).
Supplementation with L. rhamnosus combined with L. reuteri
was also studied as adjunctive therapy for patients with active RA
(Pineda et al., 2011). In this study, patients on stable medication
(for at least one month) with DMARDs, steroids and/or NSAIDs
were randomized to receive one capsule taken twice daily, for
3 months or placebo. The probiotic group received a supplement
containing L. rhamnosus GR-1 and L. reuteri RC-14 (containing
2 × 109 CFU/capsule). The placebo group received a capsule
containing the same ingredients without the bacteria. A decrease
in serum levels of IL-1a, IL-6, IL-10, IL-12p70, and TNF was
reported, but placebo caused a significantly greater decline in the
production of IL-6, IL-12p70, and TNF, as well as IL-15, IL-17.
Finally, although there was a significant improvement in the
HAQ score in the probiotic group, no between-group differences
were found (Pineda et al., 2011).
Randomized Controlled Trials With Lactobacillus
casei
A different strain of Lactobacillus, L. casei, was also studied for its











































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Pharmacology | www.frontiersin.org July 2021 | Volume 12 | Article 7117889
Ferro et al. Probiotic Supplementation for Rheumatoid Arthritis
Mehrabany et al., patients with inactive to moderate RA (i.e., a
disease activity score (DAS28) of <5.1) who were following a stable
medication regimen for at least three months were included;
current medication for most patients included DMARDs and
GCs, but not NSAIDs or biologics. The probiotic group
received a daily capsule of L. casei 01 (>108 CFU/capsule) for
eight weeks (Vaghef-Mehrabany et al., 2014). The placebo group
received capsules containing only maltodextrin (the excipient used
in the probiotic capsules). The probiotic supplementation
significantly decreased three of the assessed serum pro-
inflammatory cytokines (TNF, IL-6, and IL-12). Moreover, a
significant increase in serum levels of IL-10 was observed in the
probiotic group. In this study, the pain visual analogue scale (VAS)
score decreased, compared with baseline, by 43.96% in the
probiotic group and by 5.99% in the placebo group at the end
of the study (Vaghef-Mehrabany et al., 2014). Regarding the effects
of probiotic supplementation with L. casei on oxidative stress,
Vaghef-Mehrabany et al. conducted a secondary analysis and
concluded that this intervention had no significant effect on the
oxidative status of patients with RA compared to placebo (Vaghef-
Mehrabany et al., 2016). Additionally, the same authors found that
this intervention with L. casei 01 also significantly decreased serum
high sensitivity C-reactive protein (hs-CRP), global health score
(assessed by VAS), DAS-28, as well as tender and swollen joint
counts (Alipour et al., 2014). Regarding disease activity, DAS-28
(mean ± standard deviation) decreased from 2.56 ± 1.01 at baseline
to 2.07 ± 0.82 at the end of the study in the probiotic group, while a
much smaller improvement in DAS-28 was observed in the placebo
group (2.31 ± 0.90 at baseline to 2.23 ± 0.86 at the end of the study)
(Alipour et al., 2014).
Zamani et al. tested L. casei combined with other strains (Zamani
et al., 2016). In this RCT, the intervention group received, in addition
to their conventional medications (DMARDs and GCs), a daily
capsule containing L. casei (2 × 109 CFU/g), L. acidophilus (2 ×
109 CFU/g) and B. bifidum (2 × 109 CFU/g) for eight weeks, and
the placebo group took capsules filled with cellulose for the same
amount of time. Although this trial was conducted in patients with
moderate to severe disease activity (DAS-28 > 3.2), contrarily to the
previous studies, probiotic supplementation also resulted in improved
DAS-28. In the probiotic group, DAS-28 (mean ± standard deviation)
decreased from 4.0 ± 0.7 at baseline to 3.7 ± 0.7 at the end of the trial,
while the decrease in the placebo group was only from 4.1 ± 0.7 at
baseline to 4.0 ± 0.7 at the end of the trial. The authors also found a
significant decrease in serum hs-CRP concentrations and other
parameters not previously studied, such as serum insulin levels
(Zamani et al., 2016). In line with Vaghef-Mehrabany et al., this
intervention did not influence biomarkers of oxidative stress compared
with the placebo among patients with RA (Zamani et al., 2016).
Lastly, L. casei was also tested combined with other strains in
the study conducted by Cannarella et al. (Cannarella et al., 2021).
In this trial, RA patients in the probiotic group took a daily sachet
for 60 days containing 109 CFU/g of each of the following strains:
L. casei LC-11, L. acidophilus LA-14, Lactococcus lactis LL-23, B.
lactis BL-04 and B. bifidum BB-06, and the placebo group took
maltodextrin daily for the same amount of time. Similarly to the
previous studies, the usual medication was maintained in both
groups during the experiment. The probiotic group showed a
significant reduction in white blood cell counts, TNF and IL-6
plasma levels, but this intervention did not alter DAS-28 (median
of 3.83 at baseline vs a median of 3.88 at the end of the study in the
placebo group; median of 3.20 at baseline vs a median of 3.18 at
the end of the study in the probiotic group). Moreover, no
differences were found in the IL-10, adiponectin, CRP and
erythrocyte sedimentation rate (ESR) between groups. The
authors also assessed parameters that were not reported in the
previous studies, such as oxidative/nitrosative profile and
antioxidant defences. They found that probiotic supplementation
improved the oxidative/nitrosative profile and increased the
antioxidant defences in patients with RA. In this regard, the
probiotic group showed lower nitric oxide metabolites, and
higher sulfhydryl group and a total radical-trapping antioxidant
parameter compared to the placebo group (Cannarella et al., 2021).
Randomized Controlled Trials With Bacillus coagulans
An RCT with B. coagulansGBI-30, 6,086® (GanedenBC30®), also
used in combination with DMARDs, was conducted by Mandel
et al. in RA patients. In this trial, besides the probiotic itself, the
preparation included green tea extract, methylsulfonylmethane,
vitamins and minerals, and the placebo contained
microcrystalline cellulose. There was a statistically significant
improvement in the pain scale compared to placebo (Mandel
et al., 2010). Besides, the probiotic supplementation resulted in a
reduction of CRP and greater improvement in patient-global
assessment, self-assessed disability, the ability to walk two miles
and participation in daily activities compared to placebo (Mandel
et al., 2010). The authors did not report DAS-28 but suggested
that B. coagulans GBI-30, 6,086® supplementation may be an
effective adjunct therapy for the relief of RA symptoms. Trials
assessing disease activity are warranted.
Summary of Evidence From Randomized
Controlled Trials
Overall, there is some evidence from human RCTs that probiotic
supplementation can improve disease activity and the
inflammatory status of RA patients when used in addition to
the patient’s conventional medications. Additionally, the recently
published RCT by Cannarella et al. reported that probiotic
supplementation could also increase the antioxidant defences
and improve oxidative/nitrosative profile in RA patients
(Cannarella et al., 2021). Figure 3 summarizes the
experimental evidence for the use of probiotic bacteria in RA
according to taxonomic distribution.
Several different strains have been tested for their benefit in
RA patients, as single species or in mixed culture, in different
dosages, which is a limitation that could explain conflicting
results. Selecting the most appropriate strain for
administration to RA patients is of major importance, and this
should be sought in future research projects. As of now, probiotic
supplementation with L. casei seems to be the strongest candidate
to be used as adjuvant therapy for RA patients, and current
evidence suggests a minimum of 108 CFU/capsule per day to
obtain significant results. Supporting this, a systematic review and
meta-analysis investigating the effectiveness of probiotic
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supplementation in RA underlined that the trials in which a
significant reduction of CRP was achieved used the same
probiotic strain, L. casei (Rudbane et al., 2018). Nevertheless,
strain choice is only one of the various variables that are likely to
influence the outcomes of probiotic studies, because dosage, study
duration, frequency of administration, baseline disease activity
(Marco and Tachon, 2013) and concomitant pharmacological
treatment are also of major importance. Table 2 details the
characteristics and main findings of the included papers
regarding probiotic effects on RA.
FERMENTED FOODS AS A POSSIBLE
ALTERNATIVE TO PROBIOTIC
SUPPLEMENTS
Fermented foods and beverages are defined as foods made
through desired microbial growth and enzymatic conversions
of food components (Marco et al., 2021). Yoghurt, Kefir, Miso,
Natto, Tempeh and most Kombuchas are some of the available
fermented foods that contain live microorganisms (Marco et al.,
2021). Historically, many foods have undergone fermentation as a
food preservation technique (Paul Ross et al., 2002; Dimidi et al.,
2019) since the generation of antimicrobial metabolites like
organic acids, ethanol and bacteriocins reduce the risk of
contamination with pathogenic microorganisms (Dimidi et al.,
2019). Nowadays, fermented foods and beverages are more
popular than ever before (Bell et al., 2018). This emerging
interest in such foods could be explained by their health-
promoting potential (Marco et al., 2017; Melini et al., 2019).
Although the current body of evidence regarding the impact of
fermented foods on health and disease remains insufficient (Bell et al.,
2018; Dimidi et al., 2019), it is increasingly understood that some
fermented foods promote human health in ways not directly
attributable to the starting food materials (Marco et al., 2017).
These foods could benefit health through the nutritive alteration
of the ingredients, modulation of the immune system, or by
influencing GM composition and activity (Marco et al., 2021).
Most likely, several of these mechanisms are related and
contribute to the effects of each other.
These foods contain various microbes with health-promoting
properties, and GM has been suggested to be the mediator
between fermented food consumption and these health
outcomes. However, it is important to acknowledge that
changes in the bacterial composition of diet do not necessarily
translate into GM functional changes (Stiemsma et al., 2020).
That being said, there is evidence from dietary interventions in
humans suggesting that foodborne microbes can transiently
colonize gut (David et al., 2014). Food ingested bacteria are
capable of transient integration into GM, despite the resistance
of resident communities to colonization by ingested bacteria
(Derrien and van Hylckama Vlieg, 2015). Although these
microorganisms are unlikely to maintain long-term residence
in the intestine, it has been suggested that short-term colonization
could be sufficient to synthesize bioactive compounds, inhibit
intestinal pathogens and mediate epithelial modulatory effects
(Marco et al., 2021). Nevertheless, to fully understand the long-
term effects of the consumption of fermented foods, it is crucial
that future studies have longer intervention periods and evaluate
the GM composition, not only before and immediately after the
FIGURE 3 | Taxonomic distribution of probiotic bacteria used in animal models of arthritis and rheumatoid arthritis trials.
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TABLE 2 | Probiotic effects on Rheumatoid Arthritis in clinical trials.
Author/ year Sample size/ study
duration/ RA severity





n  21/12 months/
mild disease
L. rhamnosus GG ≥5 × 109 CFU/capsule (4 caps/day) HAQ; TJC and SJC; ESR; CRP; IL-1β;
IL-6; IL-10; IL-12; TNF
No statistical differences were observed;
↑ number of subjects reporting subjective
well being in the probiotic group





2 × 109 CFU/capsule (2 caps/day) TJC and SJC; ESR; CRP; TNF; IL-1 α;
IL-1β; IL-6; IL-10; IL-12; GH VAS; pain
VAS; HAQ








L. casei 01 ≥108 CFU/capsule (1 caps/day) IL-1β; IL-6; IL-10; IL-12;TNF ↓ IL-6; ↓ IL-12; ↓ TNF;↑ IL-10
(Alipour et al., 2014) n  46/8 weeks/mild
to moderate disease




n  46/8 weeks/mild
to moderate disease
L. casei 01 ≥108 CFU/capsule (1 caps/day) MDA; SOD; GPx; CAT; TAC No significant effect was observed on the
oxidative status





2x109 CFU/g of each strain
(1 caps/day)
DAS28; TJC and SJC; VAS of pain;
hs-CRP; serum insulin; HOMA-B;
HOMA-IR; lipid profile; NO; TAC;
GSH; MDA













109 CFU/sachet of each strain
(1 sachet/day)
DAS28; GH VAS; TJC and SJC; WBC;
ESR; hs-CRP; TNF; IL-6; IL-10;
adiponectin; LOOH; PC; NO; SH
↓ WBC; ↓ TNF;↓ IL-6; ↓ NOx;↑ Total









2x109 CFU/day HAQ-DI; TJC and SJC; ERS; CRP; pain
score; global assessment
↓ pain score and CRP
B, bifidobacterium; CAT, catalase; CRP, C-reactive protein; DAS28, disease activity score 28 joint count; ESR, erythrocyte sedimentation rate; GH, global health; GSH, glutathione; GPx, glutathione peroxidase; HAQ, Health Assessment
Questionnaire; HAQ-DI, Stanford Health Assessment Questionnaire Disability Index; HOMA-B, homeostatic model assessment-B cell function; HOMA-IR, homeostasis model of assessment-estimated insulin resistance; hs-CRP, serum high
sensitivity C-reactive protein; IL, interleukin; L, lactobacillus; LOOH, lipid hydroperoxide; MDA, malondialdehyde; NO, nitric oxide; NOx, nitric oxid metabolites; PC, protein carbonyl; RCT, randomized clinical trial; RA, rheumatoid arthritis; SH,
sulfhydryl groups; SJC, swollen joint counts; SOD, superoxide dismutase; TAC, total antioxidant capacity; TJC, tender joint counts; TNF, tumour necrosis factor; TRAP, total radical-trapping antioxidant parameter; VAS, visual analogue scale;


































intervention, but also some time after the cessation of the regime
(e.g., several weeks). Bifidobacterium and lactic acid bacteria,
including Lactobacillus, which were studied as probiotic
supplements in RA patients, are some of the microorganisms
present in many fermented foods (Tamang et al., 2016).
Even though fermented foods can be classified as probiotics if
they meet the required criteria, it is important to clarify that
fermented foods are not equivalent to probiotic foods since many
fermented foods do not have evidence of a demonstrated health
benefit conferred by well-defined and characterized live
microorganisms (Hill et al., 2014; Marco et al., 2021). The
effects of the microorganisms are strain specific and most
likely dose-dependent. This is one of the main limitations
regarding the use of fermented foods as an alternative to
probiotic supplementation. Additionally, some foods and
beverages produced by fermentation do not contain live
microorganisms, such as bread, beer, wine and distilled
alcoholic beverages, due to their inactivation by heat or physical
removal by filtration or other means (Rezac et al., 2018). As
previously discussed, fermented foods could lead to beneficial
outcomes by various mechanisms besides providing living
microorganisms to the gastrointestinal tract. Hence, these foods
could carry a positive functional role even in the absence of live
microorganisms in the finished product, considering that microbes
are capable of modifying food constituents, may produce vitamins
or other bioactive molecules and inactivate anti-nutritional factors
(Marco et al., 2017; Rezac et al., 2018). Since several other
components in the food matrix may positively influence health
and it is possible that fermented foods carry additional benefits
when compared with probiotic supplementation by itself.
Considering all these findings, fermented foods can be probiotic
carriers and may be a promising alternative to probiotic
supplementation for RA patients. Fermented foods may change
the amounts and types of beneficial bacteria that live in human
gut (Stiemsma et al., 2020) and, considering the emerging evidence
linking dysbiosis with autoimmunity mechanisms (Horta-Baas et al.,
2017), this could be particularly interesting for RA patients.
Moreover, there is evidence of the beneficial effect of fermented
foods in reducing inflammatory biomarkers in studies conducted in
healthy individuals (Burton et al., 2017; Pei et al., 2017). Of interest to
the subject discussed in this paper, fermented foods have also been
studied in other inflammatory conditions and, although more
research is needed, results suggested that these foods can exert
beneficial effects in conditions characterized by chronic
inflammation. For instance, an RCT conducted in patients with
inflammatory bowel disease found that kefir consumption
significantly decreased ESR and CRP serum levels in patients with
Crohn’s disease and concluded that this intervention may improve
both symptoms and quality of life of these patients (Yılmaz et al.,
2019). Furthermore, in patients with type 2 diabetes, the
consumption of a probiotic yogurt containing 3.7 × 106 CFU/g of
both L. acidophilus (La5) and B. lactic (Bb12), significantly decreased
TNF levels (Mohamadshahi et al., 2014). A significant decrease in
TNF levels, as a result of yogurt consumption, was also found in a
RCT promoted by Chen et al., conducted in obese women with
nonalcoholic fatty liver disease and metabolic syndrome (Chen et al.,
2019). In this study conventional yogurt was used and a significant
decrease in serum lipopolysaccharide (LPS), a biomarker of gut
permeability, was also found as well as changes in GM
composition, namely a decrease in the abundance of the
Firmicutes phylum and the taxa within it (Chen et al., 2019). In
line with this, a recent systematic review and meta-analysis of RCTs
regarding fermented foods and inflammation reported that
fermented foods might have beneficial effects in subjects with an
inflammatory disease background (SaeidiFard et al., 2020), as is the
case of RA patients. Lastly, dietary interventions are among the
nonpharmacological therapies proposed to minimize the
consequences of the disease in patients with established RA
(Küçükdeveci, 2019). Finally, it has already been suggested that
fermented foods may be an appealing complement to a whole-
dietary pattern, such as the Mediterranean Diet, since both
fermented foods and the Mediterranean Diet have similar anti-
inflammatory pathways and may potentiate each other, resulting
in a promising combination for RA patients (Dourado et al., 2020).
Altogether, this evidence highlights the need for well conducted
intervention studies with fermented foods in RA patients.
CONCLUSION
The link between gut dysbiosis and RA has expanded the interest in
investigating the modulation of the GM as a possible adjuvant
therapy for disease prevention and treatment. The increasing
evidence reporting the positive effects of probiotic bacteria in
animal models of arthritis has been leveraging the desire to
transfer these benefits into clinical practice. However, only a small
number of studies addressed the role of probiotics in themanagement
of RA on human subjects and, to the best of our knowledge, no
human trial has investigated the role of probiotics in a preventive
approach. Research in this field is still in need of high-quality studies
with larger sample sizes and longer treatment durations to ascertain
the exact benefit of this promising treatment for RA patients.
Probiotics supplementation in RA seems to have no clinically
significant adverse effects, but further research is needed to get a solid
basis concerning the most appropriate strains for RA patients. As of
now, L. casei seems to be the strongest candidate, and its potential
effect on GM and immune system could be further explored to
achieve new insights on this promising therapy for RA patients.
Moreover, fermented foods may be a possible alternative to
probiotic supplementation, as some of these foods and beverages
are known to be probiotic carriers with potentially similar health
benefits. As the current body of evidence investigating the impact
of fermented foods on health and disease remains insufficient, its
proposed benefits on the human GM should warrant future
research consideration.
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